Latest Financial Position News

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

Prairie Lithium has fast-tracked its flagship Saskatchewan lithium project by initiating fabrication of a commercial-scale extraction unit and securing vital rail access, supported by a US$5 million non-dilutive capital raise and a promising offtake agreement.

Xstate Resources has secured $3.82 million through a two-tranche capital raising to advance appraisal and production testing at its Diona-1 well in Queensland, positioning the company for critical flow testing and further exploration.

Livium Ltd has completed its strategic pivot to focus on recycling clean energy waste, reporting solid Q1 FY26 results and securing a significant capital raise to fuel expansion into battery, solar panel, and rare-earth element recycling.

BCAL Diagnostics has secured key partnerships and a $10 million convertible note facility to expand its cancer detection tests across Australia and New Zealand, marking steady commercial progress in Q3 2025.

BSA Limited’s Q1 FY2026 results reveal a sharp revenue drop following the expiration of its key nbn contract, alongside a major workforce reduction and strategic pivot.

Race Oncology has filed pivotal patents on the active (E,E)-bisantrene isomer, potentially extending its drug exclusivity by two decades, while advancing its Phase 1 clinical trial and maintaining a strong cash position.

Antilles Gold advances its Cuban mining ambitions with a binding EPC contract signed and construction slated to begin early next year at the Nueva Sabana copper-gold project.

Jindalee Lithium reported a challenging quarter with over A$2 million in cash outflows but bolstered its funding position with a recent $8 million share placement, extending its operational runway.

Australian Gold and Copper Ltd has significantly expanded its South Cobar exploration footprint through key acquisitions and reported strong high-grade drilling results at its Achilles deposit, underpinning its growth strategy.

Percheron Therapeutics reports encouraging phase I clinical results for HMBD-002, confirming safety and early efficacy signals, while gearing up for a multi-arm phase II trial in 2026.

Venus Metals Corporation reports a significant update to its Sandstone gold resource, formalizes a joint venture with IGO at Bridgetown-Greenbushes, and reveals promising zinc and indium mineralisation at Youanmi.